Hospitals are facing persistent drug shortages, which puts patients at risk and leaves caregivers scrambling for alternative therapies.
Since it was founded in 2018, Civica Rx – a nonprofit generic drug company – has vowed to address chronic generic drug shortages in the U.S. and stabilize the supply of essential generic medications in hospitals and health care systems.
Typical drugs in short supply include generic injectable medications like Vancomycin and Daptomycin, which are essential to treating life-threatening infections.
In partnership with generic drug manufacturer Xellia Pharmaceuticals, Civica will soon deliver these antibiotics to approximately 900 hospitals in the U.S. Vancomycin and Daptomycin are the first two of 14 hospital-administered generic drugs Civica has committed to deliver as the initial focus.
“We thank Xellia for helping to lead the way in efforts to reduce chronic generic drug shortages in the U.S., including treatments for serious infections caused by bacteria that are resistant to other antibiotics,” said Martin VanTrieste, President and CEO of Civica. “By helping to stabilize the supply of Vancomycin and Daptomycin, we will have a direct impact on patient safety and public health by providing consistent access to antibiotics that are important treatment options in the management of difficult-to-treat and life-threatening infections.”
Civica will continue to work with trusted manufacturing partners that have FDA-approved manufacturing plants in the U.S. like Xellia to stabilize the supply of drugs in critical short supply, while also working towards becoming an FDA-approved manufacturer in the long term.
Headquartered in Copenhagen, Denmark, Xellia has a longstanding heritage of manufacturing with an emphasis on quality and security of supply. The company will make medications for Civica under Xellia’s Abbreviated New Drug Application (ANDA) and Civica labeling and New Drug Code (NDC).
Why Civica Rx?
Hospital patients should have access to life-saving medications.Learn More